Source/Disclosures
Source:

Healio Interview

Disclosures: Jacobs reports receiving research funding from Pharmacyclics and TG Therapeutics, Inc. and speakers' bureau fees from AbbVie, AstraZeneca, Genentech, Janssen Pharmaceuticals and Pharmacyclics and serving on advisory boards for AbbVie and Pharmacyclics.
November 25, 2020
1 min watch
Save

Future developments in CLL reside in testing, CAR T-cell therapy

Source/Disclosures
Source:

Healio Interview

Disclosures: Jacobs reports receiving research funding from Pharmacyclics and TG Therapeutics, Inc. and speakers' bureau fees from AbbVie, AstraZeneca, Genentech, Janssen Pharmaceuticals and Pharmacyclics and serving on advisory boards for AbbVie and Pharmacyclics.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Ryan W. Jacobs, MD, discussed next-generation treatments for novel targets and other developments on the horizon for chronic lymphocytic leukemia, including perfecting CAR T-cell therapy.

“I also see another area where the science is probably going to be moving and will hopefully result in smart treatment decisions for the right patients is the utilization of minimal disease residue testing,” Jacobs, head of the clinical trials program for CLL at Atrium Health’s Levine Cancer Institute, said.

 

Click here for the next video in this series.